TABLE 3.
Adverse events.
| Toxicity | Grade 1 | Grade 2 | Grade 3 | p‐value | |||
|---|---|---|---|---|---|---|---|
| Group BP‐1 N (%) | Group C N (%) | Group BP‐1 N (%) | Group C N (%) | Group BP‐1 N (%) | Group C N (%) | ||
| Neutropenia | 10 (23.81) | 14 (28.57) | 6 (14.29) | 9 (18.37) | 1 (2.38) | 2 (4.08) | 0.778 |
| Anemia | 8 (19.05) | 15 (30.61) | 8 (19.05) | 4 (8.16) | 0 (0.00) | 1 (2.04) | 0.209 |
| Thrombocytopenia | 9 (21.43) | 7 (14.29) | 1 (2.38) | 2 (4.08) | ‐ | ‐ | 0.624 |
| Sensory neuropathy | 5 (11.90) | 6 (12.24) | 1 (2.38) | 3 (6.12) | 1 (2.38) | 0 (0.00) | 0.509 |
| Nausea and vomiting | 5 (11.90) | 17 (34.69) | 2 (4.76) | 16 (32.65) | 0 (0.00) | 2 (4.08) | <0.001 |
| Anorexia | 10 (23.81) | 22 (44.90) | 1 (2.38) | 6 (12.24) | ‐ | ‐ | 0.007 |
| Constipation | 7 (16.67) | 26 (53.06) | 0 (0.00) | 5 (10.20) | ‐ | ‐ | <0.001 |
| Diarrhea | 3 (7.14) | 13 (26.53) | 0 (0.00) | 7 (14.29) | 0 (0.00) | 1 (2.04) | <0.001 |
| Fatigue | 19 (45.24) | 21 (42.86) | 7 (16.67) | 10 (20.41) | 0 (0.00) | 2 (4.08) | 0.413 |
| Pain | 3 (7.14) | 7 (14.29) | 2 (4.76) | 6 (12.24) | ‐ | ‐ | 0.201 |
| Dyspnea | 3 (7.14) | 6 (12.24) | 0 (0.00) | 3 (6.12) | ‐ | ‐ | 0.098 |
| Insomnia | 5 (11.90) | 5 (10.20) | 3 (7.14) | 5 (10.20) | ‐ | ‐ | 0.857 |
| Dizziness | 3 (7.14) | 5 (10.20) | 1 (2.38) | 0 (0.00) | ‐ | ‐ | 0.408 |
| Alopecia | 4 (9.52) | 3 (6.12) | 2 (4.76) | 2 (4.08) | ‐ | ‐ | 0.816 |